Trial Profile
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Nelitolimod (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Malignant melanoma; Nasopharyngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms KEYNOTE-184; SYNERGY-001
- Sponsors Dynavax Technologies
- 29 Dec 2021 Results (n=51) published in the Clinical Cancer Research
- 11 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 24 Feb 2020 This trial has been completed in Germany,according to European Clinical Trials Database record.